01:44

Challenges in fluid biomarker development in Alzheimer's disease research

01:13

Neuroprotective effects of transcription factor NRF2 in Alzheimer’s disease mice models

03:09

How are blood-based biomarkers currently used in Alzheimer’s disease?

01:12

ALZ-801 in combination with anti-amyloid antibodies for the treatment of Alzheimer’s disease

02:39

Distinguishing between late-onset primary psychiatric disorders and dementia

01:45

Promise of tau-PET imaging for Alzheimer's disease

04:22

Prognostic accuracy of plasma NfL to predict Alzheimer’s disease dementia

01:01

Neuroimaging and fluid biomarkers in early-onset Alzheimer’s disease

01:34

Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia

05:19

Examining plasma vs. CSF p-tau217 in preclinical and prodromal Alzheimer’s disease

03:07

How goes audiovisual gamma stimulation provide benefit in Alzheimer's disease?

01:33

BACE1 inhibitors: investigating the mechanisms of cognitive worsening

01:15

Evolving use of tau-specific fluid biomarkers for Alzheimer's disease

01:53

LEADS: shedding light on early-onset Alzheimer's disease

01:36

The challenges of using animal models in Alzheimer’s research

05:15

Diagnostic performance of plasma p-tau217 in a memory clinic cohort

03:31

ALZ-801 Phase II data & launch of Phase III study in early Alzheimer’s disease

00:54

The preventative potential of gamma frequency stimulation for preclinical Alzheimer’s disease

01:42

Exploring the cognitive impact of BACE1 inhibition for Alzheimer’s disease

00:51

Will blood-based biomarkers replace PET for trial recruitment?

08:35

Using machine learning to predict progression from subject cognitive decline to Alzheimer’s disease

04:19

Current projects from Alzheimer’s Disease International

01:24

Digital frailty screening in dementia

00:50

Will long-term anti-amyloid treatment show greater clinical benefit?

02:33

Anti-amyloid therapy for Alzheimer's disease: beyond the 18-month mark

04:44

Influence of genetic risk for psychiatric disorders on dementia

04:12

Updates in Alzheimer’s treatment: the potential of NSC001

03:58

Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease

01:20

The importance of a timely diagnosis for cognitive decline

04:28

Most patients excluded from using current anti-amyloid therapies in Alzheimer’s disease

04:13

Therapeutics for AD: addressing the lack of affordability

02:06

The role of governments in addressing the access issues to dementia treatment

02:31

Barriers to dementia treatment: awareness, accessibility, and affordability

05:29

Insights into the use of PROTACs in Alzheimer’s disease

02:06

The potential of ALZ-801 as an oral small molecule treatment for Alzheimer’s disease

04:41

Insights into cellular signatures of cognitive resilience

02:41

Updates on tau topography and propagation

02:39

Investigating p-tau217 as a clinical screening tool

06:03

Gamma frequency stimulation as a treatment for Alzheimer’s disease

02:35

Revisiting BACE inhibitors: the potential of BACE1 for delaying Alzheimer’s onset

04:20

Quantifying tau pathology patterns in young-onset Alzheimer’s disease

04:55

Enhancing trials to prove disease modification in early Alzheimer's disease

01:37

Recommendations for the deployment of second-generation memory clinics

02:03

Future developments in imaging techniques for vascular cognitive impairment

02:13

Emerging imaging techniques in the diagnosis of vascular cognitive impairment

03:07

Navigating challenges in the diagnosis of vascular cognitive impairment

03:16

Implementation of EEG as a biomarker in Alzheimer's disease diagnosis and treatment monitoring

02:13

Long-term validity of amyloid-PET in a memory clinic population

02:05

Exploring the impact of CT1812 on EEG biomarkers in Alzheimer's disease: a pilot study

05:40

Plasma p-tau217 screening identifies individuals most likely to benefit from anti-amyloid therapy

07:49

Targeting brain metabolism in Alzheimer’s disease: results from the PIONEER trial

04:29

Improving imaging analysis in clinical trials and routine practice

08:29

Key issues for diagnosis and treatment of patients with Alzheimer's disease in Latin America

04:41

Future targets for treatment of Alzheimer's disease

03:10

Enhancing clinical trials: central EEG analysis for optimal research insights

02:44

New research into amyloid-PET: impact of different amyloid accumulation patterns

03:41

Amyloid-PET in the age of blood-based biomarkers

01:48

EEG changes seen in Alzheimer’s disease

04:21

Phase II trial of ACU193 in Alzheimer’s disease

03:27

What does the future of Alzheimer’s diagnosis look like?